1079103-87-9

Upstream product

• 64-17-5 ethanol 
• 1079103-86-8 4-(3-cyclopropyl-5-iodo-1H-pyrazol-4-yloxy)-2,6-dimethyl-benzonitrile 
• 201230-82-2 carbon monoxide 

Downstream Products

• 1079103-99-3 4-(4-cyano-3,5-dimethyl-phenoxy)-5-cyclopropyl-2-(2-methoxy-ethyl)-2H-pyrazole-3-carboxylic acid ethyl ester 
• 1079103-95-9 4-(4-cyano-3,5-dimethyl-phenoxy)-5-cyclopropyl-1-methyl-1H-pyrazole-3-carboxylic acid ethyl ester 
• 1079103-92-6 4-(4-cyano-3,5-dimethyl-phenoxy)-5-cyclopropyl-2-methyl-2H-pyrazole-3-carboxylic acid ethyl ester 
• 1079103-98-2 4-(4-cyano-3,5-dimethyl-phenoxy)-5-cyclopropyl-2-ethyl-2H-pyrazole-3-carboxylic acid ethyl ester 
• 1079103-89-1 4-(4-cyano-3,5-dimethyl-phenoxy)-5-cyclopropyl-2-methylsulfanylmethyl-2H-pyrazole-3-carboxylic acid ethyl ester 
• 1079103-88-0 4-(4-cyano-3,5-dimethyl-phenoxy)-5-cyclopropyl-1-methylsulfanylmethyl-1H-pyrazole-3-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

Synthetic studies on a nonsteroidal progesterone metabolite: Regioselective N-alkylation of an activated pyrazole

This paper describes the large-scale synthesis of a progesterone receptor metabolite. The key step in this sequence was the regioselective pyrazole N-alkylation. Georg Thieme Verlag Stuttgart - New York.

OXYALKYLPYRAZOLE COMPOUNDS USEFUL IN THERAPY

A compound of Formula (IA) or (IB), or a pharmaceutically acceptable salt, solvate (including hydrate) of said compound and salt, or a prodrug of said compound, or a pharmaceutically acceptable salt or solvate of said prodrug, Formula (IA), (IB) wherein t